Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 96 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Overactive Bladder (OAB) Clear all
Terminated Phase 3 Interventional Results available

Over Active Bladder Instillation Study - Botox

NCT00667095
View directory record Official record
Conditions
Overactive Bladder, Urinary Urge Incontinence, Urinary Incontinence, Detrusor Hyperreflexia, Urge Incontinence
Interventions
Botox Instillation, DMSO Instillation
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 11, 2014 · Synced Oct 23, 2026, 4:45 PM EDT
Completed Phase 4 Interventional

A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men.

NCT00333112
View directory record Official record
Conditions
Urinary Incontinence
Interventions
solifenacin succinate, tamsulosin, placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
45 Years and older · Male only
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
74
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tuscon, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 23, 2026, 4:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genomics and Epigenomics for New Insights in fEmale OAB (GENIE) Study

NCT03057158
View directory record Official record
Conditions
Overactive Bladder, Insulin Resistance
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
257 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Oct 23, 2026, 4:45 PM EDT
Recruiting No phase listed Observational

Intradetrusor Onabotulinumtoxin A (Botox) at the Time of Transurethral Resection of the Prostate or Transurethral Waterjet Ablation of the Prostate for Mixed Lower Urinary Tract Symptoms

NCT07377929
View directory record Official record
Conditions
Benign Prostatic Hypertrophy (BPH), Lower Urinary Track Symptoms
Interventions
Survey using a questionnaire.
Other
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 23, 2026, 4:45 PM EDT
Completed Phase 2 Interventional

Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women

NCT03475706
View directory record Official record
Conditions
Overactive Bladder
Interventions
Solabegron immediate release tablets, low dose, Solabegron immediate release tablets, high dose, Matching Placebo
Drug
Lead sponsor
Velicept Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
86
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 77 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 23, 2026, 4:45 PM EDT
Recruiting Not applicable Interventional

Tensi+ for Treating Overactive Bladder

NCT07300904
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
Tensi+
Device
Lead sponsor
Stimuli Technology
Industry
Eligibility
22 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Beverly Hills, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 23, 2026, 4:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

TEST-ON - Does iStim Reduce Urinary Urgency?

NCT04957524
View directory record Official record
Conditions
Overactive Bladder, Urgency-frequency Syndrome, Urinary Frequency More Than Once at Night
Interventions
iStim TENS unit and Transvaginal Probe
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 23, 2026, 4:45 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)

NCT02138747
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
Mirabegron, Tolterodine ER
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
22
States / cities
Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 23, 2026, 4:45 PM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076

NCT01655069
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Solifenacin succinate suspension
Drug
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
5 Years to 17 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Oct 23, 2026, 4:45 PM EDT
Completed Phase 4 Interventional

Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder

NCT00127270
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Darifenacin, Behavioral therapy
Drug · Behavioral
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
395 participants
Timeline
2005 – 2006
U.S. locations
67
States / cities
Birmingham, Alabama • Tucson, Arizona • Culver City, California + 58 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2008 · Synced Oct 23, 2026, 4:45 PM EDT
Terminated Not applicable Interventional Results available

Foot/Hand Neuromodulation for Overactive Bladder (OAB)

NCT01972061
View directory record Official record
Conditions
Overactive Bladder
Interventions
Foot stimulation
Device
Lead sponsor
Christopher J Chermansky, MD
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 23, 2026, 4:45 PM EDT
Not listed Not applicable Interventional

CAN-Stim Compared to SNS in Treatment of Urinary Urgency Incontinence With Wireless Neuromodulation Technology

NCT02577302
View directory record Official record
Conditions
Urinary Incontinence, Urge
Interventions
CAN-Stim - Protect CAN-Stim System, SNS - InterStim® System
Device
Lead sponsor
Uro Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
15
States / cities
Laguna Hills, California • Los Angeles, California • Orange, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 23, 2026, 4:45 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Posterior Tibial Nerve Stimulation (PTNS) Plus Mirabegron to Treat Refractory OAB Symptoms (PTNS-M Study)

NCT04907032
View directory record Official record
Conditions
Overactive Bladder
Interventions
Mirabegron 50 MG, Posterior Tibial Nerve Stimulation (PTNS)
Drug · Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Oct 23, 2026, 4:45 PM EDT
Terminated No phase listed Observational

A Pilot Trial in a Sleep Laboratory Setting to Observe Night Time Bladder Function of Subjects With Overactive Bladder (OAB)

NCT01099345
View directory record Official record
Conditions
Bladder Function
Interventions
cystometry (CMG), polysomnography (PSG)
Procedure
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 4, 2014 · Synced Oct 23, 2026, 4:45 PM EDT
Recruiting No phase listed Observational

Assessing the Genitourinary Microbiome of Women With Overactive Bladder Undergoing Onabotulinum Toxin Type A Intradetrusor Injections

NCT07025044
View directory record Official record
Conditions
Overactive Bladder (OAB), Urge Incontinence
Interventions
onabotulinum toxin type a
Drug
Lead sponsor
Alexis Dieter
Other
Eligibility
55 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 23, 2026, 4:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

This Is A Study Of Bioavailability And Food Effect For Fesoterodine.

NCT01286454
View directory record Official record
Conditions
Overactive Bladder (OAB) With Symptoms of Frequency, Urgency, and Urgency
Interventions
fesoterodine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 26, 2012 · Synced Oct 23, 2026, 4:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Bacterial Genomic Sequencing in Overactive Bladder

NCT01642277
View directory record Official record
Conditions
Overactive Bladder
Interventions
Solifenacin
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 23, 2026, 4:45 PM EDT
Recruiting Phase 2 Interventional

Zinc Supplementation With Botulinum Toxin for Overactive Bladder

NCT07405554
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
Zinc Citrate Oral Capsule, Placebo
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
21 Years to 100 Years · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Skokie, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 23, 2026, 4:45 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

NCT03902080
View directory record Official record
Conditions
Overactive Bladder
Interventions
Vibegron, Placebo
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
45 Years and older · Male only
Enrollment
1,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
75
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 23, 2026, 4:45 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

NCT02757768
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Overactive Bladder
Interventions
Mirabegron, Placebo, Tamsulosin Hydrochloride
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
40 Years and older · Male only
Enrollment
715 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
32
States / cities
Homewood, Alabama • Huntsville, Alabama • Anchorage, Alaska + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 23, 2026, 4:45 PM EDT
Completed Phase 4 Interventional Results available

Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life

NCT00573508
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Placebo, Solifenacin Succinate
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
768 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
59
States / cities
Montgomery, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2010 · Synced Oct 23, 2026, 4:45 PM EDT
Terminated Not applicable Interventional

A Sham-Controlled Study to Evaluate the Safety and Efficacy of a Smart, Self-Adjusting, Surgery-Free, Wearable Bladder Neuromodulation System for Overactive Bladder

NCT05381116
View directory record Official record
Conditions
Overactive Bladder, Urinary Urge Incontinence, Urge Incontinence
Interventions
Avation System, Sham Avation System
Device
Lead sponsor
Avation Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
6
States / cities
Tucson, Arizona • Oak Lawn, Illinois • New Orleans, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 23, 2026, 4:45 PM EDT
Completed Phase 2 Interventional

Study of AOBO-001 for Overactive Bladder With Urge Urinary Incontinence and Frequency

NCT01294982
View directory record Official record
Conditions
Overactive Bladder
Interventions
AOBO-001, Placebo
Drug
Lead sponsor
American Oriental Bioengineering, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Mobile, Alabama • West Palm Beach, Florida • Newton, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 23, 2026, 4:45 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)

NCT02216214
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
Mirabegron, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
65 Years and older
Enrollment
888 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
103
States / cities
Huntsville, Alabama • Mobile, Alabama • Anchorage, Alaska + 88 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 23, 2026, 4:45 PM EDT